XOMA Royalty Corporation delivered strong third-quarter 2025 financial results, reporting significant growth in royalty receipts and completing multiple strategic acquisitions to expand its biotechnology royalty portfolio. The biotech royalty aggregator received $43.9 million in royalties and milestones from partners during the first nine months of 2025, with $14.3 million generated from royalties in the third quarter alone.
"We continue to execute on innovative ways to increase optionality within our portfolio while maintaining a healthy cash balance and limiting dilution to our shareholders," stated Owen Hughes, Chief Executive Officer of XOMA Royalty. "Growing royalty receipts reflect solid commercial execution on the part of our partners. We look forward to several clinical readouts over the coming months and quarters that, if positive, can meaningfully shape our business trajectory."
Strategic Acquisitions Drive Portfolio Expansion
XOMA Royalty completed the acquisitions of Turnstone Biologics for $0.34 in cash per share plus contingent value rights (CVRs) and HilleVax for $1.95 per share plus CVRs. The company also announced planned acquisitions of LAVA Therapeutics for $1.04 per share plus CVRs and Mural Oncology for between $2.035 and $2.24 per share, with the Mural acquisition expected to close in Q4 2025.
Through the LAVA Therapeutics acquisition, XOMA Royalty will secure economic interests in two early-stage partnered assets: PF-08046052 being developed by Pfizer and JNJ-89853413 being developed by Johnson & Johnson. The company also acted as structuring agent for XenoTherapeutics' completed acquisition of ESSA Pharma.
Key Pipeline Milestones and Regulatory Progress
Several significant developments occurred across XOMA Royalty's partner portfolio. Zevra Therapeutics submitted a Marketing Authorization Application (MAA) with the European Medicines Agency (EMA) seeking marketing approval for arimoclomol as a treatment for Niemann-Pick Type C disease on July 28, 2025.
Rezolute Bio reconfirmed expectations to announce topline data in December 2025 from its Phase 3 ersodetug trial (sunRIZE) in patients with congenital hyperinsulinism and announced FDA alignment on a streamlined design for its ongoing Phase 3 trial of ersodetug in tumor hyperinsulinism, with topline results expected in the second half of 2026.
Takeda dosed the first patient in its Phase 3 clinical trial investigating mezagitamab as a treatment for adults with IgA Nephropathy. Gossamer Bio activated the first clinical site for its global Phase 3 SERANATA study examining seralutinib in patients with pulmonary hypertension associated with interstitial lung disease and expects topline results from its Phase 3 PROSERA trial of seralutinib in pulmonary arterial hypertension in February 2026.
Strong Financial Performance
XOMA Royalty reported net income of $14.1 million for Q3 2025, a significant improvement from the net loss of $17.2 million in Q3 2024. For the nine months ended September 30, 2025, the company achieved net income of $25.6 million compared to a net loss of $9.9 million in the corresponding 2024 period.
Income and revenue for the three and nine months ended September 30, 2025, were $9.4 million and $38.4 million, respectively, compared with $7.2 million and $19.8 million for the corresponding periods of 2024. The increase was primarily driven by increased income related to VABYSMO and OJEMDA.
Tom Burns, Chief Financial Officer of XOMA Royalty, commented, "In the first nine months of 2025, we have received $43.9 million in cash from partners, of which $30.3 million were royalty payments related to commercial sales and $13.6 million in milestone payments and fees. With well-executed commercialization efforts by our partners and the emergence of new commercial opportunities from within our portfolio, XOMA Royalty has the potential to become a self-sustaining entity from royalties alone over the near term."
Cash Position and Capital Allocation
On September 30, 2025, XOMA Royalty maintained a strong cash position with $130.6 million in cash and cash equivalents, including $85.4 million in restricted cash. The restricted cash balance included $43.3 million related to the assumed HilleVax lease, $39.9 million reserved to fund the Mural acquisition, and $2.2 million related to the Blue Owl Loan.
During the first nine months of 2025, XOMA Royalty deployed $25.0 million to acquire additional assets for its royalty and milestone portfolio, repurchased approximately 108,510 shares of its common stock for $2.4 million, and paid $4.1 million in dividends on the XOMA Royalty Perpetual Preferred stocks.
Upcoming Catalysts
Looking ahead, XOMA Royalty anticipates several key events that could impact its business trajectory. Rezolute is expected to announce topline data from its sunRIZE Phase 3 clinical trial investigating ersodetug in infants and children with congenital hyperinsulinism in December 2025. Day One Biopharmaceuticals' partner Ipsen expects to receive an EMA regulatory decision on its application to commercialize tovorafenib in the European Union.
Daré Bioscience plans to make its DARE to PLAY Sildenafil Cream available commercially via prescription in Q4 2025 as a compounded drug and will commence one of two registrational Phase 3 clinical trials investigating Sildenafil Cream, 3.6%, for the treatment of female sexual arousal disorder.
The company's commercial assets currently include VABYSMO (faricimab-svoa), OJEMDA (tovorafenib), MIPLYFFA (arimoclomol), XACIATO (clindamycin phosphate) vaginal gel 2%, IXINITY [coagulation factor IX (recombinant)], and DSUVIA (sufentanil sublingual tablet), with all other portfolio assets representing investigational compounds in development.
